Lloyd Damon, MD

Director of Blood and Bone Marrow Transplant

Dr. Lloyd Damon is director of the adult Blood and Marrow Transplant and Hematologic Malignancies Program and chief of the UCSF Hematology Clinic. He is a hematologist, cancer specialist or oncologist, and researcher who specializes in cancers of the blood such as lymphomas and leukemias. In his research, he studies new treatments for acute myeloid and acute lymphoblastic leukemias. In 1995, he was one of the early investigators in the first monoclonal antibody, called rituximab, approved to treat human cancer, specifically lymphoma. In 1998, he developed a high-dose regimen involving autologous stem cell transplants for mantle cell lymphoma. He also discovered the risk factors for an uncommon brain side effect of an important leukemia drug, cytarabine, and developed a dose modification algorithm that reduced this side effect to extremely low levels.

Damon earned a medical degree at the University of Michigan. He completed an internal medicine residency and hematology-oncology fellowship at UCSF, where he joined the faculty in 1988. He is a professor of clinical medicine and deputy chief of the Division of Hematology and Medical Oncology at UCSF.


Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Conditions & Treatments

Academic Title


More about Lloyd Damon


University of Michigan 1982


UCSF, Internal Medicine 1985


UCSF, Hematology/Oncology 1988

Selected Research and Publications

  1. Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, Barta SK, Boyer MW, Bryan T, Burke PW, Cassaday R, Coccia PF, Coutre SE, Damon LE, DeAngelo DJ, Frankfurt O, Greer JP, Kantarjian HM, Klisovic RB, Kupfer G, Litzow M, Liu A, Mattison R, Park J, Rubnitz J, Saad A, Uy GL, Wang ES, Gregory KM, Ogba N. NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. J Natl Compr Canc Netw. 2017 Sep; 15(9):1091-1102.
  2. Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 11; 22(11):1974-1982.
  3. Damon LE. The use of ibrutinib in chronic lymphocytic leukemia. Clin Adv Hematol Oncol. 2016 Mar; 14(3):154-6.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.